Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), For Intravenous Inf...

FDA Recall #D-0336-2024 — Class II — January 23, 2024

Recall #D-0336-2024 Date: January 23, 2024 Classification: Class II Status: Ongoing

Product Description

Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), For Intravenous Infusion Only, 250 mL vial, Rx Only, Baxter Healthcare Corporation, Deerfield, IL 60015. Made in Ireland. NDC: 0338-0108-20

Reason for Recall

Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg / 250 mL.

Recalling Firm

Baxter Healthcare Corporation — Deerfield, IL

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

13,000 bags

Distribution

Nationwide in the USA

Code Information

Lot 23I21G64; Exp. 07/31/2024

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated